HRP20150449T1 - Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima - Google Patents

Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima

Info

Publication number
HRP20150449T1
HRP20150449T1 HRP20150449TT HRP20150449T HRP20150449T1 HR P20150449 T1 HRP20150449 T1 HR P20150449T1 HR P20150449T T HRP20150449T T HR P20150449TT HR P20150449 T HRP20150449 T HR P20150449T HR P20150449 T1 HRP20150449 T1 HR P20150449T1
Authority
HR
Croatia
Prior art keywords
multiplog
myeloma
antibodies
treatment
methods
Prior art date
Application number
HRP20150449TT
Other languages
English (en)
Croatian (hr)
Inventor
Daniel Afar
Kenneth C. Anderson
Yu-Tzu Tai
Original Assignee
Abbvie Biotherapeutics Inc.
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150449(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc., Dana-Farber Cancer Institute, Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of HRP20150449T1 publication Critical patent/HRP20150449T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
HRP20150449TT 2006-08-07 2007-08-07 Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima HRP20150449T1 (xx)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
EP07840746.7A EP2068874B1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
HRP20150449T1 true HRP20150449T1 (xx) 2015-06-05

Family

ID=38831279

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150449TT HRP20150449T1 (xx) 2006-08-07 2007-08-07 Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima
HRP20161284TT HRP20161284T1 (hr) 2006-08-07 2016-10-06 METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20161284TT HRP20161284T1 (hr) 2006-08-07 2016-10-06 METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM

Country Status (23)

Country Link
US (4) US8632772B2 (OSRAM)
EP (5) EP2068874B1 (OSRAM)
JP (1) JP5340935B2 (OSRAM)
CN (1) CN101686971B (OSRAM)
AU (1) AU2007281684C1 (OSRAM)
BR (1) BRPI0716647A2 (OSRAM)
CA (1) CA2660356C (OSRAM)
CY (5) CY1116247T1 (OSRAM)
DK (2) DK2641601T3 (OSRAM)
ES (2) ES2535437T3 (OSRAM)
HR (2) HRP20150449T1 (OSRAM)
HU (4) HUE029027T2 (OSRAM)
IL (2) IL196919A (OSRAM)
LT (4) LT2641601T (OSRAM)
LU (3) LU93276I2 (OSRAM)
MX (1) MX2009001441A (OSRAM)
NL (1) NL300840I2 (OSRAM)
NO (1) NO346835B1 (OSRAM)
NZ (1) NZ574978A (OSRAM)
PL (2) PL2641601T3 (OSRAM)
PT (2) PT2641601T (OSRAM)
SI (2) SI2068874T1 (OSRAM)
WO (1) WO2008019378A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
HUE029027T2 (en) 2006-08-07 2017-01-30 Abbvie Biotherapeutics Inc Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
JP2011523560A (ja) 2008-06-02 2011-08-18 ダナ−ファーバー キャンサー インスティテュート インク． Ｘｂｐ１ペプチド、ｃｄ１３８ペプチドおよびｃｓ１ペプチド
NZ589880A (en) 2008-06-16 2012-10-26 Immunogen Inc Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate
PE20120059A1 (es) * 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
EP2476438B1 (en) * 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
CA2780998C (en) * 2009-11-24 2016-07-12 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015069785A1 (en) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
CA2924268C (en) * 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
LT3182996T (lt) * 2014-08-22 2023-03-10 Celgene Corporation Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
BR112017011538A2 (pt) * 2014-12-04 2018-03-13 Bristol-Myers Squibb Company combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
HRP20210552T1 (hr) 2015-05-13 2021-05-14 Morphosys Ag Liječenje multiplog mijeloma (mm)
ES2886657T3 (es) * 2015-06-29 2021-12-20 Bristol Myers Squibb Co Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
CN109432398A (zh) * 2016-03-13 2019-03-08 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
SG11201907923VA (en) 2017-03-29 2019-09-27 Agency Science Tech & Res Anti oligosaccharide antibody
JP2021504475A (ja) * 2017-11-22 2021-02-15 ヒルストリーム・バイオファーマ・インコーポレイテッド ボルテゾミブを含むポリマーナノ粒子
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
KR20220092578A (ko) 2019-11-05 2022-07-01 브리스톨-마이어스 스큅 컴퍼니 M-단백질 검정 및 이의 용도
CN115368462A (zh) * 2022-07-19 2022-11-22 合肥天港免疫药物有限公司 双特异性抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
WO1996037208A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2752140A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1824513A4 (en) * 2004-11-04 2010-06-09 Fibron Ltd TREATMENT OF B-CELL TUMORS
JP2010500370A (ja) 2006-08-07 2010-01-07 ピーディーエル バイオファーマ，インコーポレイティド 多発性硬化症を処置するための抗ｃｓ１抗体を用いる組成物および方法
HUE029027T2 (en) 2006-08-07 2017-01-30 Abbvie Biotherapeutics Inc Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells

Also Published As

Publication number Publication date
PT2641601T (pt) 2016-10-14
IL196919A0 (en) 2009-11-18
NO346835B1 (no) 2023-01-23
EP2641601B8 (en) 2016-09-21
CN101686971B (zh) 2013-09-11
JP2010500371A (ja) 2010-01-07
HUS1600043I1 (hu) 2016-12-28
EP2641600A1 (en) 2013-09-25
CY2016038I1 (el) 2017-07-12
HUS1600044I1 (hu) 2016-12-28
ES2535437T3 (es) 2015-05-11
AU2007281684C1 (en) 2013-12-19
IL196919A (en) 2016-03-31
WO2008019378A1 (en) 2008-02-14
DK2068874T3 (da) 2015-04-27
US8632772B2 (en) 2014-01-21
LTPA2016031I1 (lt) 2016-11-10
NL300840I2 (OSRAM) 2017-01-03
ES2589302T3 (es) 2016-11-11
LT2641601T (lt) 2016-10-10
NO20090968L (no) 2009-04-30
US20080152646A1 (en) 2008-06-26
EP2641601B1 (en) 2016-07-06
AU2007281684A1 (en) 2008-02-14
CY2016036I1 (el) 2017-07-12
CY1117992T1 (el) 2017-05-17
LTPA2016029I1 (lt) 2016-11-10
LTPA2016030I1 (lt) 2016-11-10
SI2641601T1 (sl) 2016-11-30
LTC2068874I2 (lt) 2018-11-12
CA2660356A1 (en) 2008-02-14
AU2007281684B2 (en) 2013-05-16
EP3115049A1 (en) 2017-01-11
LU93277I2 (fr) 2016-12-27
SI2068874T1 (sl) 2015-06-30
DK2641601T3 (en) 2016-08-22
CY2016036I2 (el) 2017-07-12
LU93276I2 (fr) 2016-12-27
CA2660356C (en) 2016-04-05
NZ574978A (en) 2012-08-31
CN101686971A (zh) 2010-03-31
HRP20161284T1 (hr) 2016-12-16
LU93275I2 (fr) 2016-12-27
EP2068874B1 (en) 2015-01-28
EP2942057A1 (en) 2015-11-11
IL243933A0 (en) 2016-04-21
EP2641601A1 (en) 2013-09-25
HK1129853A1 (en) 2009-12-11
CY2016037I1 (el) 2017-07-12
HUS1600045I1 (hu) 2016-12-28
US20140322201A1 (en) 2014-10-30
CY1116247T1 (el) 2017-02-08
MX2009001441A (es) 2009-07-06
PT2068874E (pt) 2015-05-21
HUE029027T2 (en) 2017-01-30
JP5340935B2 (ja) 2013-11-13
US20160137735A1 (en) 2016-05-19
US20170342150A1 (en) 2017-11-30
BRPI0716647A2 (pt) 2017-05-16
PL2641601T3 (pl) 2017-01-31
PL2068874T3 (pl) 2015-06-30
EP2068874A1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
HRP20150449T1 (xx) Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
LTPA2016005I1 (lt) Anti-il-5 antikūnų skyrimo būdai
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
EP2254597A4 (en) TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK2182983T3 (da) Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
HUE048404T2 (hu) Claudin-18 elleni monoklonális antitestek rák kezelésére
HUE036477T2 (hu) Monoklonális anti-GT468 antitestek rák kezeléséhez
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
DK2004204T3 (da) Behandling af neurodegenerative sygdomme med selenat
EP2084185A4 (en) HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme
FI20060995A0 (fi) Luonnollisen kielen käsittely
HRP20181728T1 (hr) Postupci liječenja analne inkontinencije mioblastima
EP2281575A4 (en) ANTIBODIES FOR THE TREATMENT OF CANCER
FI20070037A0 (fi) Menetelmä jätteen käsittelemiseksi
HK1146811A (en) Methods of treatment using anti-mif antibodies
BRPI0716580A2 (pt) Tratamento de distúrbios fibrosantes